Total Valuation
Innovent Biologics has a market cap or net worth of €20.96B. The enterprise value is €122.92K.
Market Cap€20.96B
Enterprise Value€122.92K
Share Statistics
Innovent Biologics has 1,743,682,600 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1,743,682,600
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Innovent Biologics’s return on equity (ROE) is 0.04 and return on invested capital (ROIC) is 2.39%.
Return on Equity (ROE)0.04
Return on Assets (ROA)0.02
Return on Invested Capital (ROIC)2.39%
Return on Capital Employed (ROCE)0.03
Revenue Per Employee1.74M
Profits Per Employee111.83K
Employee Count7,502
Asset Turnover0.35
Inventory Turnover2.34
Valuation Ratios
The current PE Ratio of Innovent Biologics is 130.2. Innovent Biologics’s PEG ratio is -0.15.
PE Ratio130.2
PS Ratio9.09
PB Ratio6.12
Price to Fair Value6.12
Price to FCF12.72
Price to Operating Cash Flow15.76
PEG Ratio-0.15
Income Statement
In the last 12 months, Innovent Biologics had revenue of 13.04B and earned 813.57M in profits. Earnings per share was 0.48.
Revenue13.04B
Gross Profit10.00B
Operating Income733.62M
Pretax Income838.92M
Net Income813.57M
EBITDA1.31B
Earnings Per Share (EPS)0.48
Cash Flow
In the last 12 months, operating cash flow was 10.09B and capital expenditures -269.59M, giving a free cash flow of 9.82B billion.
Operating Cash Flow10.09B
Free Cash Flow9.82B
Free Cash Flow per Share5.63
Dividends & Yields
Innovent Biologics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.25
52-Week Price Change20.30%
50-Day Moving Average9.81
200-Day Moving Average9.36
Relative Strength Index (RSI)72.63
Average Volume (3m)532.00
Important Dates
Innovent Biologics upcoming earnings date is Mar 31, 2027, TBA (Confirmed).
Last Earnings DateAug 25, 2026
Next Earnings DateMar 31, 2027
Ex-Dividend Date―
Financial Position
Innovent Biologics as a current ratio of 2.62, with Debt / Equity ratio of 11.20%
Current Ratio2.62
Quick Ratio2.47
Debt to Market Cap0.02
Net Debt to EBITDA-11.09
Interest Coverage Ratio9.46
Taxes
In the past 12 months, Innovent Biologics has paid 25.36M in taxes.
Income Tax25.36M
Effective Tax Rate0.03
Enterprise Valuation
Innovent Biologics EV to EBITDA ratio is 79.39, with an EV/FCF ratio of 11.16.
EV to Sales7.98
EV to EBITDA79.39
EV to Free Cash Flow11.16
EV to Operating Cash Flow10.40
Balance Sheet
Innovent Biologics has €18.24B in cash and marketable securities with €2.82B in debt, giving a net cash position of €15.42B billion.
Cash & Marketable Securities€18.24B
Total Debt€2.82B
Net Cash€15.42B
Net Cash Per Share€8.84
Tangible Book Value Per Share€10.76
Margins
Gross margin is 80.96%, with operating margin of 5.63%, and net profit margin of 6.24%.
Gross Margin80.96%
Operating Margin5.63%
Pretax Margin6.43%
Net Profit Margin6.24%
EBITDA Margin10.05%
EBIT Margin5.63%
Analyst Forecast
The average price target for Innovent Biologics is €14.45, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target€14.45
Price Target Upside21.91% Upside
Analyst ConsensusStrong Buy
Analyst Count18
Revenue Growth Forecast32.59%
EPS Growth Forecast1.94%